Latest Ratios: P/E Ratio -0.1x · EV/EBITDA -0.0x · ROE -243.9%. (2003–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $2M | $73M | $380M | $380M | $1.5B | $761M | $663M | $336M | $347M | $723M |
| Enterprise Value | $-1916851 | $-2482956 | $73M | $377M | $369M | $1.5B | $745M | $646M | $316M | $341M | $719M |
| P/E Ratio → | -0.11 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.13 | 0.20 | — | 119.95 | 29.21 | 57.04 | 45.21 | 38.50 | 16.09 | 54.96 | 243.67 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | -0.00 | -0.00 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -243.9% | -243.9% | -714.9% | -255.4% | -72.4% | -72.5% | -155.1% | -81.7% | -72.9% | -145.0% | -182.2% |
| ROA | -170.6% | -170.6% | -328.3% | -209.4% | -66.5% | -67.0% | -137.5% | -74.5% | -67.8% | -116.8% | -139.0% |
| ROIC | -417.9% | -417.9% | — | -1416.2% | -972.3% | -19448.1% | -84585.0% | -3213.3% | -1457.5% | -2184.6% | — |
| ROCE | -232.0% | -232.0% | -714.3% | -256.0% | -72.2% | -71.5% | -151.2% | -81.9% | -73.5% | -144.8% | -222.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | — | 0.10 | 0.05 | 0.03 | 0.05 | 0.06 | 0.01 | 0.01 | 0.02 |
| Debt / EBITDA | 0.00 | 0.00 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.50 | — | -1.00 | -0.83 | -1.00 | -0.99 | -1.00 | -0.96 | -0.96 | -1.35 |
| Net Debt / EBITDA | -0.01 | -0.01 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -11.70 | -11.70 | -353.30 | -674.22 | -945.06 | -996.18 | -2493.58 | -2131.37 | -1712.41 | -31.07 | -2063.46 |
Net cash position: cash ($4M) exceeds total debt ($227348)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.64 | 5.64 | 0.87 | 2.15 | 8.95 | 19.17 | 13.40 | 10.18 | 18.79 | 8.01 | 3.14 |
| Quick Ratio | 5.64 | 5.64 | 0.87 | 2.15 | 8.95 | 19.17 | 13.40 | 10.18 | 18.79 | 8.01 | 3.14 |
| Cash Ratio | 4.70 | 4.70 | 0.51 | 1.94 | 7.16 | 18.87 | 13.14 | 9.87 | 17.31 | 6.86 | 3.04 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | 0.1% | — | — | 0.0% | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $2M | $7M | $2M | $2M | $2M | $942187 | $704732 | $217318 | $82104 | $74348 |
Includes 30+ ratios · 23 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OGEN stock.
Oragenics, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Oragenics, Inc.'s current EV/EBITDA is -0.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
Oragenics, Inc.'s return on equity (ROE) is -243.9%. The historical average is -150.7%.
Based on historical data, Oragenics, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Oragenics, Inc.'s Debt/EBITDA ratio is 0.0x, indicating low leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Imminent liquidity and dilution
Metrics are mathematically derived from official filings.
Speculative Valuation Lacks Fundamental Support
According to recent financial data, OGEN trades at a P/B ratio of 0.15, which, based on reported figures, suggests the market assigns negligible value to the company's intellectual property or pipeline potential relative to its historical book value and ongoing research-driven capital depletion.
The extremely low P/B multiple indicates that investors are heavily discounting the company's assets, likely reflecting skepticism regarding the commercial viability of the intranasal vaccine platform. This valuation suggests the market views the firm as a distressed entity rather than a growth-stage biotechnology company, with little to no premium attributed to its proprietary technology.
Capital Destruction Through Research Intensity
As reported in financial statements, the company's ROIC has remained deeply negative, reaching -79.8% in 2026Q1, which illustrates that the firm is currently consuming capital at an unsustainable rate without generating any offsetting returns from its clinical development activities.
The persistent negative ROIC highlights the structural challenge of a pre-revenue business model where every dollar invested in R&D results in immediate value erosion. Investors should monitor whether future clinical milestones can reverse this trend, though current data suggests that the company is effectively destroying shareholder value through its current operational trajectory.
Liquidity Buffer Facing Severe Pressure
Based on the latest quarterly data, the company's current ratio has fluctuated wildly, dropping from 133.42 in 2026Q1 to levels as low as 0.71 in 2025Q2, which indicates a highly unstable liquidity position that leaves the firm vulnerable to sudden funding shocks.
The extreme volatility in the current ratio reflects the company's reliance on periodic equity financing to maintain operations. This lack of a stable liquidity buffer suggests that the firm may face significant operational disruptions if it cannot secure additional capital in the near term.
Structural Lag Versus Peer Group
As evidenced by peer comparison data, OGEN lags behind established biotech entities like ADMA Biologics, which maintains a positive ROE of 39.0%, whereas OGEN's negative returns underscore its structural disadvantage as a pre-commercial firm compared to peers with active revenue streams.
While peers like Vaxart and ADMA have successfully transitioned to commercial or late-stage clinical status, OGEN remains stuck in a pre-revenue phase. This gap appears structural rather than temporary, as the company lacks the diversified revenue base that provides its peers with greater financial resilience.
Misapplication of Price-to-Book Ratios
Investors frequently misapply the P/B ratio to OGEN, as reported in financial statements, because this metric fails to account for the intangible nature of biotechnology pipelines, where the true value resides in clinical data rather than the tangible assets reflected on the balance sheet.
Relying on P/B for a pre-revenue biotech firm obscures the potential for binary outcomes, as the book value is largely irrelevant to the company's future success. A more appropriate focus would be the 'cash runway' or 'burn rate' relative to clinical milestones, which better captures the actual risk of insolvency.